Vertex Pharmaceuticals VRTX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's accrued liabilities, current?
- Vertex Pharmaceuticals (VRTX) reported accrued liabilities, current of $2.98B in Q1 2026.
- How has Vertex Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Vertex Pharmaceuticals's accrued liabilities, current increased by 1.1% year-over-year, from $2.95B to $2.98B.
- What is the long-term trend for Vertex Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accrued liabilities, current has grown at a 16.2% compound annual growth rate (CAGR), from $1.41B to $2.97B.